🔗 Visit the ClinicalTrials.gov page for NCT01781429
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. | Clin Cancer Res | 2015 | 2.12 |
| 2 | Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. | Oncotarget | 2014 | 1.33 |
| 3 | ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. | Cancer Res | 2014 | 0.96 |
| 4 | Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. | Cancer Cell | 2015 | 0.96 |
| 5 | The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. | Am J Med Genet A | 2016 | 0.76 |
| 6 | Other targeted drugs in melanoma. | Ann Transl Med | 2015 | 0.75 |